João Sérgio

Dec 6, 2024 | academic.oup.com | Joao Pedro |Université de Lorraine |João Sérgio |Baylor Scott

Many patients with heart failure (HF) and a preserved ejection fraction have anaemia as a consequence of ‘chronic disease’.

Nov 7, 2024 | karger.com | Joao Pedro |Ana Cristina |Ana Rita |João Sérgio

Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRAs) reduce the progression of kidney disease. Whether the combination of these agents provides additional benefits compared to SGLT2i alone is worth exploring using data from randomized trials designed for this purpose. Aims: To assess the randomized treatment effect of MRAs combined with SGLT2i vs SGLT2i alone on markers of kidney and cardiovascular health.

Aug 8, 2023 | eprints.gla.ac.uk | João Sérgio |Del Prato |John V |Joao Pedro

Neves, J. S. et al. (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. 517-525. (doi: 10.1016/j.jacc.2023.05.048) (PMID:37532422) Full text not currently available from Enlighten. AbstractBackground:Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D).

Mar 31, 2023 | paperity.org | João Sérgio

Acta Diabetologica, Mar 2023 This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007/s00592-023-02070-7.pdf Ferreira, Margarida, Neves, João Sérgio, Neves, Celestino, Carvalho, Davide. , Acta Diabetologica, 2023, pp. 1-9, DOI: 10.1007/s00592-023-02070-7